Role of Investigators in Adverse Event Documentation in Clinical Trials
Investigators play a direct role in maintaining compliance with global safety regulations:
Click to read the full article.
Safety Reporting and Pharmacovigilance
Grading Adverse Event Severity Using CTCAE Guidelines in Clinical Trials
The Common Terminology Criteria for Adverse Events (CTCAE) is a descriptive terminology that provides a grading scale (1–5) for the severity of AEs. The current version, CTCAE v5.0, is widely used in oncology and non-oncology trials to ensure harmonized reporting.
Click to read the full article.
Causality Assessment in Adverse Event Reporting: A Practical Guide for Clinical Trials
Causality assessment is the systematic evaluation of the likelihood that an adverse event (AE) was caused by the investigational product or another factor. This evaluation is essential for classifying AEs, especially when reporting serious adverse events (SAEs) to sponsors and regulatory agencies like USFDA or CDSCO.
Click to read the full article.
How to Capture Adverse Events in Electronic Case Report Forms (eCRFs)
Clinical Research Associates (CRAs) verify AE entries against source documentation during on-site or remote monitoring. They ensure:
Click to read the full article.
Documenting AE Follow-Up and Resolution in Clinical Trials
If the AE was classified as a Serious Adverse Event (SAE), additional follow-up forms are often required. These include:
Click to read the full article.
Auditing Risk Management Plan Effectiveness: Best Practices and Procedures
Risk Management Plan effectiveness refers to how well the implemented risk minimization activities achieve their intended safety objectives. It encompasses:
Click to read the full article.
Training Site Staff on Adverse Event Reporting in Clinical Trials
Effective AE reporting starts with effective training. A well-structured program ensures that all site staff—from coordinators to PIs—understand their responsibilities and are equipped to handle adverse event data professionally. By investing in continuous AE education, sponsors and sites can significantly improve trial safety outcomes, data integrity, and regulatory confidence.
Click to read the full article.
Examples of Risk Management Plans for Biologics
Biologics differ from small-molecule drugs in their source, structure, and mechanisms of action. These differences introduce risks such as:
Click to read the full article.
Criteria for Defining Serious Adverse Events in Clinical Research
According to the ICH E6(R2) and ICH E2A guidelines, a serious adverse event (SAE) is an adverse event (AE) that meets at least one of the following seriousness criteria. It is critical to distinguish SAEs from general AEs to comply with mandatory safety reporting timelines.
Click to read the full article.
Stakeholder Communication Within Risk Management Plans (RMPs)
Clear and timely communication of product risks ensures that appropriate decisions are made at every level—from prescribing to monitoring and reporting. Poor communication can result in:
Click to read the full article.